Author(s):
C. U. Pavithra, K. Swetha, S. Ivo Romauld, P. Brindhadevi
Email(s):
ivoromauld@gmail.com
DOI:
10.5958/0974-360X.2020.00703.9 
Address:
C. U. Pavithra, K. Swetha, S. Ivo Romauld, Dr. P. Brindhadevi
Department of Bio-Engineering, VISTAS, Chennai - 600117, Tamil Nadu, India.
*Corresponding Author
Published In:
Volume - 13,
Issue - 8,
Year - 2020
ABSTRACT:
Multiple sclerosis (MS) is a disease which causes demyelination of the brain cells and spinal cord nerve cells. During the diseased conditions, the axon doesn’t perform its function. Myelin acts like insulation electrical wires since the nerves are affected by loss of myelin and the patient with multiple sclerosis will lack the ability of axons to conduct impulses. The multiple sclerosis is considered as autoimmune disorder, the exact cause hasn’t yet been found. Many theories regarding the reason that people develop MS range from vitamin C deficiency to a viral infection. Consuming increased salt content food is being looked at as possible cause of MS. This review focuses on the existing Drug- Dimethylfumarate and Fingolimod and the possibilities of Tamil medicines for its effective cure of MS. It is found that for curing relapsing and remitting Dimethylfumarate and fingolimod is used along with natural medicines (Brahmi leaves, ginger, Bermuda grass) is used to fight against the existing symptoms of MS. In addition to preventing potential complications of being sedentary, such as deconditioning, osteoporosis, obesity or vascular comorbidities, physical exercise can play an important role in managing symptoms in persons with MS and may possibly be neuroprotective.
Cite this article:
C. U. Pavithra, K. Swetha, S. Ivo Romauld, P. Brindhadevi. A Review on Multiple Sclerosis and its Regimens. Research J. Pharm. and Tech. 2020; 13(8):3977-3982. doi: 10.5958/0974-360X.2020.00703.9
Cite(Electronic):
C. U. Pavithra, K. Swetha, S. Ivo Romauld, P. Brindhadevi. A Review on Multiple Sclerosis and its Regimens. Research J. Pharm. and Tech. 2020; 13(8):3977-3982. doi: 10.5958/0974-360X.2020.00703.9 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2020-13-8-76
REFERENCES:
1. Hauser SL, Goodin DS. Multiple sclerosis and other demyelinating diseases. Harrisons Principles of Internal Medicine. 2005;16(2):2461.
2. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg‐Wollheim M. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 2001 Jul;50(1):121-7.
3. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg‐ Wollheim M. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 2001 Jul;50(1):121-7.
4. Yetkin FZ, Haughton VM, Papke RA, Fischer ME, Rao SM. Multiple sclerosis: specificity of MR for diagnosis. Radiology. 1991 Feb;178(2):447-51.
5. Burness CB, Deeks ED. Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis. CNS Drugs. 2014 Apr 1; 28(4):373-87.
6. Chen H, Assmann JC, Krenz A, Rahman M, Grimm M, Karsten CM, Köhl J, Offermanns S, Wettschureck N, Schwaninger M. Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE. The Journal of Clinical Investigation. 2014 May 1;124(5):2188-92.
7. de Jong R, Bezemer AC, Zomerdijk TP, van de Pouw‐Kraan T, Ottenhoff TH, Nibbering PH. Selective stimulation of T helper 2 cytokine responses by the anti‐psoriasis agent monomethylfumarate. European Journal of Immunology. 1996 Sep;26(9):2067-74.
8. Ghoreschi K, Brück J, Kellerer C, Deng C, Peng H, Rothfuss O, Hussain RZ, Gocke AR, Respa A, Glocova I, Valtcheva N. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. Journal of Experimental Medicine. 2011 Oct 24;208(11):2291-303.
9. Calabresi PA, Goodin D, Jeffery D, Kappos L, Lublin F, Rammohan K. Efficacy and safety of fingolimod versus placebo: primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing–remitting multiple sclerosis. Mult Scler. 2012 Oct 10;18 (suppl 4):205.
10. Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Neurology. 2014 Jun 1;13(6):545-56.
11. Coyle P, Cree B, Cabre P, Inglese M, Perumal J, Meng X, Chin P, Hashmonay R, Khan O. Fingolimod Efficacy and Safety in an African-American Patient Subgroup from Freedoms II (P3. 156).
12. Goodin D, Jeffery D, Kappos L, Lublin F, Radue EW, Rammohan K, Reder A, Vollmer T, Agius M, Stites T, Li B. Fingolimod reduces annualized relapse rate in patients with relapsing-remitting multiple sclerosis: Freedoms II study subgroup analysis (P07. 102).
13. Wattanathorn J, Mator L, Muchimapura S, Tongun T, Pasuriwong O, Piyawatkul N, Yimtae K, Sripanidkulchai B, Singkhoraard J. Positive modulation of cognition and mood in the healthy elderly volunteer following the administration of Centella asiatica. Journal of Ethnopharmacology. 2008 Mar 5;116(2):325-32.
14. Puttarak P, Dilokthornsakul P, Saokaew S, Dhippayom T, Kongkaew C, Sruamsiri R, Chuthaputti A, Chaiyakunapruk N. Effects of Centellaasiatica (L.) Urb. on cognitive function and mood related outcomes: A Systematic Review and Meta-analysis. Scientific reports. 2017 Sep 6;7(1):10646.
15. Rather MA, Thenmozhi AJ, Manivasagam T, Nataraj J, Essa MM, Chidambaram SB. Asiatic acid nullified aluminium toxicity in in vitro model of Alzheimer’s disease. Frontiers in Bioscience-Elite. 2018 Jan 1;10(2):287-99.
16. Babu DR, Neeharika V, Pallavi V, Reddy MB. Antidiarrheal activity of Cynodon Dactylon. pers. Pharmacognosy Magazine. 2009 Jul 1;5(19):23.
17. Garjani A, Afrooziyan A, Nazemiyeh H, Najafi M, Kharazmkia A, Maleki-Dizaji N. Protective effects of hydroalcoholic extract from rhizomes of Cynodondactylon (L.) Pers. on compensated right heart failure in rats. BMC Complementary and Alternative Medicine. 2009 Dec; 9(1):28.
18. Ross IA. Zingiber officinale. Medicinal Plants of the World, Volume 3: Chemical Constituents, Traditional and Modern Medicinal Uses. 2005:507-60.
19. Marsh J, Hager C, Havey T, Sprague S, Bhandari M, Bryant D. Use of alternative medicines by patients with OA that adversely interact with commonly prescribed medications. Clinical Orthopaedics and Related Research®. 2009 Oct 1;467(10):2705-22.
20. Wattanathorn J, Jittiwat J, Tongun T, Muchimapura S, Ingkaninan K. Zingiber officinale mitigates brain damage and improves memory impairment in focal cerebral ischemic rat. Evidence-Based Complementary and Alternative Medicine. 2011;2011.
21. De Tommaso M, Ambrosini A, Brighina F, Coppola G, Perrotta A, Pierelli F, Sandrini G, Valeriani M, Marinazzo D, Stramaglia S, Schoenen J. Altered processing of sensory stimuli in patients with migraine. Nature Reviews Neurology. 2014 Mar;10(3):144.
22. Moss MC, Scholey AB, Wesnes K. Oxygen administration selectively enhances cognitive performance in healthy young adults: a placebo-controlled double-blind crossover study. Psychopharmacology. 1998 Jul 1;138(1):27-33.
23. Vister E, Tijsma ME, Hoang PD, Lord SR. Fatigue, physical activity, quality of life, and fall risk in people with multiple sclerosis. International Journal of MS Care. 2017 Mar;19(2):91-8.
24. Learmonth YC, Motl RW. Physical activity and exercise training in multiple sclerosis: a review and content analysis of qualitative research identifying perceived determinants and consequences. Disability and Rehabilitation. 2016 Jun 18;38(13):1227-42.
25. Paul L, Coote S, Crosbie J, Dixon D, Hale L, Holloway E, McCrone P, Miller L, Saxton J, Sincock C, White L. Core outcome measures for exercise studies in people with multiple sclerosis: recommendations from a multidisciplinary consensus meeting. Multiple Sclerosis Journal. 2014 Oct;20(12):1641-50.
26. Alvarenga-Filho H, Sacramento PM, Ferreira TB, Hygino J, Abreu JE, Carvalho SR, Wing AC, Alvarenga RM, Bento CA. Combined exercise training reduces fatigue and modulates the cytokine profile of T-cells from multiple sclerosis patients in response to neuromediators. Journal of Neuroimmunology. 2016 Apr 15;293:91-9.
27. Bjarnadottir OH, Konradsdottir AD, Reynisdottir K, Olafsson E. Multiple sclerosis and brief moderate exercise. A randomised study. Multiple Sclerosis Journal. 2007 Jul;13(6):776-82.
28. Dalgas U, Stenager E, Jakobsen J, Petersen T, Hansen HJ, Knudsen C, Overgaard K, Ingemann-Hansen T. Fatigue, mood and quality of life improve in MS patients after progressive resistance training. Multiple Sclerosis Journal. 2010 Apr;16(4):480-90.
29. Andreasen AK, Stenager E, Dalgas U. The effect of exercise therapy on fatigue in multiple sclerosis. Multiple Sclerosis Journal. 2011 Sep;17(9):1041-54.
30. Fragoso YD, Santana DL, Pinto RC. The positive effects of a physical activity program for multiple sclerosis patients with fatigue. Neuro Rehabilitation. 2008 Jan 1;23(2):153-7.
31. Cakit BD, Nacir B, Genç H, Saraçoglu M, Karagöz A, Erdem HR, Ergün U. Cycling progressive resistance training for people with multiple sclerosis: a randomized controlled study. American Journal of Physical Medicine & Rehabilitation. 2010 Jun 1;89(6):446-57.
32. Olsen SA. A review of complementary and alternative medicine (CAM) by people with multiple sclerosis. Occupational Therapy International. 2009 Mar;16(1):57-70.
33. Leong EM, Semple SJ, Angley M, Siebert W, Petkov J, McKinnon RA. Complementary and alternative medicines and dietary interventions in multiple sclerosis: what is being used in South Australia. Complementary Therapies in Medicine. 2009 Aug 1;17(4):216-23.
34. Esmonde L, Long AF. Complementary therapy use by persons with multiple sclerosis: benefits and research priorities. Complementary Therapies in Clinical Practice. 2008 Aug 1;14(3):176-84.
35. Tremlett H, Zhao Y, Rieckmann P, Hutchinson M. New perspectives in the natural history of multiple sclerosis. Neurology. 2010 Jun 15;74(24):2004-15.
36. Comi G, Radaelli M, Sørensen PS. Evolving concepts in the treatment of relapsing multiple sclerosis. The Lancet. 2017 Apr 1;389(10076):1347-56.
37. Newland P. The use and effectiveness of alternative therapies in multiple sclerosis. Journal of Neuroscience Nursing. 1999 Feb 1;31(1):43-4.
38. Lugaresi A, Di Ioia M, Travaglini D, Pietrolongo E, Pucci E, Onofrj M. Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatric Disease and Treatment. 2013; 9: 893.
39. Marck CH, Hadgkiss EJ, Weiland TJ, Van der Meer DM, Pereira NG, Jelinek GA. Physical activity and associated levels of disability and quality of life in people with multiple sclerosis: a large international survey. BMC Neurology. 2014 Dec;14(1):143.